Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 1 to 50 of 75

TitleReference numberPublishedLast updated
Nivolumab with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancerTA1127
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancerTA1122
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancerTA1108
Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitorTA1103
Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapyTA1099
Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatmentsTA1091
Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (terminated appraisal)TA1076
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancerTA1071
Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA1072
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancerTA1060
Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal)TA1058
Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (terminated appraisal)TA1047
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resectionTA1043
Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancerTA1041
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancerTA1042
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancerTA1037
Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancerTA1030
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancerTA1021
Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancerTA1017
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancerTA1014
Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA976
Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancerTA911
Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancerTA898
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal)TA884
Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancerTA876
Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapyTA850
Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal)TA848
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancerTA812
Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiationTA798
Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterationsTA789
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancerTA781
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancerTA770
Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancerTA724
Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapyTA713
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancerTA705
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancerTA683
Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitorTA670
Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal)TA662
Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapyTA655
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancerTA653
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancerTA654
Entrectinib for treating ROS1-positive advanced non-small-cell lung cancerTA643
Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancerTA638
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal)TA635
Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancerTA628
Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal)TA618
Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancerTA595
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancerTA584
Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinibTA571
Alectinib for untreated ALK-positive advanced non-small-cell lung cancerTA536

Results per page

  1. 10
  2. 25
  3. 50
  4. All